Targeted at Tumor
Immunological anticancer drug for treatment of patients with non-resectable or metastatic melanoma has been approved in Russia. The drug by American Bristol-Myers Squibb is distinguished by its ability to activate the immune system targeting it to fight the tumor tissue. As of 2011 the drug has been used in forty countries on different continents. It is an established effective drug with good safety profile.
“In Russia, according to Larisa Tsybina, Medical Director of Bristol-Myers Squibb, from 2011 to 2016 extended access program for patients with metastatic melanoma that progressed while on standard chemotherapeutic regimen. The program provided effective treatment for 324 patients with metastatic melanoma that progressed while on standard treatment regimen”.
Drug effects are confirmed by results of numerous clinical trials.
This is the first and only immune-oncological treatment variant. It increases the overall survival median in patients with non-resectable or metastatic melanoma.